top of page
  • Active, not recruiting

NCT02891811: Phase 2: Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction

Updated: Jun 8, 2022

NCT02891811: Phase 2: Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy


ktd-krd

Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy


This is a randomized, 2-arm phase II, multi-center study to evaluate the overall response rate in newly diagnosed, transplant ineligible patients receiving 9 cycles induction therapy with either KTd or KRd followed by randomization to either carfilzomib maintenance treatment for 12 months or to observation only. Maintenance is given for 12 cycles or progression of disease, whatever occurs first.


Sponsor

Arbeitsgemeinschaft medikamentoese Tumortherapie


Collaborator

Amgen

 

ClinicalTrials.gov Identifier: NCT02891811


Official Title: A Randomized Phase II, 2-armed Study in Transplant Ineligible (TI) Patients With Newly Diagnosed Multiple Myeloma (NDMM) Comparing Carfilzomib + Thalidomide + Dexamethasone (KTd) Versus Carfilzomib + Lenalidomide + Dexamethasone (KRd) Induction Therapy With Respect to Response Rates and Investigating a Carfilzomib (K) Monotherapy Maintenance Strategy


First Posted: September 8, 2016


Click here for details on ClinicalTrials.gov

 


 

Drug: Carfilzomib

Drug: Thalidomide

Drug: Lenalidomide

Drug: Dexamethasone

 

EHA 2022 Oral Presentation

EHA 2022 - HYBRID - JUNE 9-17 - VIENNA

RANDOMIZED COMPARISON BETWEEN KRD AND KTD INDUCTION, FOLLOWED BY K MAINTENANCE OR OBSERVATION IN TRANSPLANT NON-ELIGIBLE PATIENTS WITH NDMM (AGMT-MM02 TRIAL)


 

Location

Austria

Germany







Comments


Posts Archive
bottom of page